Results 271 to 280 of about 5,004,732 (313)
Some of the next articles are maybe not open access.
AUTOANTIBODIES IN HEALTHY SUBJECTS
Australasian Annals of Medicine, 1969SUMMARYThe laboratory diagnosis of autoimmune disease depends mainly on the demonstration of autoantibodies.We determined the prevalence in an apparently healthy Australian population of the following autoantibodies : anti‐nuclear antibody, rheumatoid factor, smooth muscle antibody, anti‐mitochondrial and anti‐microsomal antibody, and antibody to ...
SENGA WHITTINGHAM +4 more
openaire +1 more source
Instrumentation to describe subjective sleep characteristics in healthy subjects
Research in Nursing & Health, 1987AbstractThe purpose of this study was to develop and test the Verran and Snyder‐Halpern (VSH) Sleep Scale, an instrument to subjectively measure sleep characteristics. Four major sleep factors and their associated characteristics were proposed for the Sleep Scale.
R, Snyder-Halpern, J A, Verran
openaire +2 more sources
Effect of sulpiride on vigilance in healthy subjects
International Journal of Psychophysiology, 1986The effects of the antipsychotic drug sulpiride on vigilance, as measured by choice reaction time and critical flicker fusion, and on heart-rate and skin conductance, were studied in healthy volunteers (n = 6). The measurements were carried out 4 and 28 h after oral and i.v. administration of 100 mg sulpiride and during placebo condition.
A, Bartfai, F A, Wiesel
openaire +2 more sources
Exenatide pharmacokinetics in healthy Chinese subjects
Int. Journal of Clinical Pharmacology and Therapeutics, 2008Exenatide is an adjunctive treatment for Type 2 diabetes. This was the first study to evaluate the pharmacokinetics, safety and tolerability of therapeutic doses (5 microg and 10 microg) of exenatide after single and multiple subcutaneous injections in healthy adult Chinese subjects.24 healthy volunteers were randomized to receive either 5 microg or 10
X, Zhao +10 more
openaire +2 more sources
Unmasking Latent Dysnociception in Healthy Subjects
Headache: The Journal of Head and Face Pain, 1987SYNOPSIS Headache is the most common side effect of nitroglycerin, administered for angina pectoris. Two phases can be distinguished in nitroglycerin‐induced headache: the first phase (immediate headache), a mild sensation of temporal pulsating pain, can be due, at least in ...
F, Sicuteri +3 more
openaire +2 more sources
Population Pharmacokinetics of Onercept in Healthy Subjects
Clinical Pharmacokinetics, 2005To develop a population pharmacokinetic model and to determine the covariates affecting the pharmacokinetics of onercept (recombinant human tumour necrosis factor [TNF] receptor-1) in healthy subjects.Onercept pharmacokinetics data were obtained from 48 healthy male and female subjects (four phase I studies). In study A, 12 subjects received increasing
Sophie, Glatt +3 more
openaire +2 more sources
Cardiac rhythm in healthy elderly subjects
The Clinical Investigator, 1992To study the normal cardiac rhythm in elderly subjects we performed 24-h Holter monitoring on 94 subjects aged over 70 years. We had previously discarded those with cardiac disease by using history, physical examination, electrocardiography (ECG), chest X-radiography and Doppler echocardiography.
A, García +7 more
openaire +2 more sources
Effect of tetrahydroaminoacridine on sleep in healthy subjects
Biological Psychiatry, 1996The present study investigated the impact of the cholinesterase inhibitor tetrahydroaminoacridine (THA; tacrine) on sleep in healthy subjects. According to the reciprocal interaction model of non-rapid eye movement (NREM) and REM sleep regulation, which postulates a primary role in cholinergic neurotransmission for the initiation and maintenance of REM
Riemann, Dieter +6 more
openaire +3 more sources
The metabolism and pharmacokinetics of fleroxacin in healthy subjects
Journal of Antimicrobial Chemotherapy, 1988A 400 mg dose of fleroxacin was administered orally to six healthy male volunteers. Concentrations of fleroxacin and the N-demethyl and N-oxide metabolites were determined in serum and urine by HPLC. The serum metabolite levels were negligible. The N-oxide metabolite was measured in the serum of five subjects but did not exceed 4% of the corresponding ...
D J, Griggs +3 more
openaire +2 more sources
Kinetics and bioavailability of mexiletine in healthy subjects
Clinical Pharmacology and Therapeutics, 1981Single-dose kinetics of mexiletine (MEX) was studied in six healthy subjects after three different formulations. The respective doses were 200 mg (intravenous infusion), 400 mg (two conventional capsules), and 432 mg (sustained-release dosage forms). By a three-compartment open model with lag time the kinetic parameters of the drug were calculated from
V, Häselbarth, J E, Doevendans, M, Wolf
openaire +2 more sources

